Next Article in Journal
Simply Adding Oxygen during Hypothermic Machine Perfusion to Combat the Negative Effects of Ischemia-Reperfusion Injury: Fundamentals and Current Evidence for Kidneys
Next Article in Special Issue
Wilson’s Disease: Facing the Challenge of Diagnosing a Rare Disease
Previous Article in Journal
Serum Selenium Level and 10-Year Survival after Melanoma
Previous Article in Special Issue
Circulating MicroRNA-21 and MicroRNA-122 as Prognostic Biomarkers in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization
Article

Protective Effects of Bee Venom-Derived Phospholipase A2 against Cholestatic Liver Disease in Mice

by 1,†, 2,†, 1,* and 3,*
1
Department of Immunology, School of Medicine, Catholic University of Daegu, Daegu 42472, Korea
2
Department of Pediatrics, School of Medicine, Keimyung University, Daegu 42601, Korea
3
Department of Emergency Medicine, School of Medicine, Catholic University of Daegu, Daegu 42472, Korea
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Marica Meroni
Biomedicines 2021, 9(8), 992; https://doi.org/10.3390/biomedicines9080992
Received: 7 July 2021 / Revised: 29 July 2021 / Accepted: 2 August 2021 / Published: 11 August 2021
Hepatocyte apoptosis and inflammation play important roles in cholestatic liver diseases. Bee venom-derived secretory phospholipase A2 (bvPLA2) has been shown to ameliorate various inflammatory diseases. However, whether bvPLA2 has a therapeutic effect against cholestatic liver disease has not been evaluated. Therefore, we investigated the effects of bvPLA2 on cholestatic liver injury and fibrosis in a murine model of 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet feeding. The administration of bvPLA2 ameliorated liver damage, cholestasis, and fibrosis in DDC diet-fed mice, as assessed by serum biochemical tests and histological examinations. In addition, bvPLA2 reduced myofibroblast accumulation, concomitant with suppression of transforming growth factor-β signaling cascade. The administration of bvPLA2 inhibited hepatocyte apoptosis in DDC diet-fed mice as represented by a reduction in the number of cells stained with terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling and suppression of caspase-3 activation. Moreover, bvPLA2 reduced cytokine production along with the inhibition of the nuclear factor kappa-B pathway. The number of regulatory T-cells was increased by bvPLA2, while the number of other immune cells, including neutrophils, macrophages, and CD8+ T-cells, was decreased. Our data indicate that the administration of bvPLA2 ameliorates cholestatic liver injury and fibrosis by inhibiting hepatocyte apoptosis and inflammation. View Full-Text
Keywords: bee venom; phospholipase A2; cholestatic liver disease; apoptosis; inflammation; fibrosis bee venom; phospholipase A2; cholestatic liver disease; apoptosis; inflammation; fibrosis
Show Figures

Figure 1

MDPI and ACS Style

Kim, J.-Y.; Jang, H.-J.; Leem, J.; Kim, G.-M. Protective Effects of Bee Venom-Derived Phospholipase A2 against Cholestatic Liver Disease in Mice. Biomedicines 2021, 9, 992. https://doi.org/10.3390/biomedicines9080992

AMA Style

Kim J-Y, Jang H-J, Leem J, Kim G-M. Protective Effects of Bee Venom-Derived Phospholipase A2 against Cholestatic Liver Disease in Mice. Biomedicines. 2021; 9(8):992. https://doi.org/10.3390/biomedicines9080992

Chicago/Turabian Style

Kim, Jung-Yeon, Hyo-Jeong Jang, Jaechan Leem, and Gyun-Moo Kim. 2021. "Protective Effects of Bee Venom-Derived Phospholipase A2 against Cholestatic Liver Disease in Mice" Biomedicines 9, no. 8: 992. https://doi.org/10.3390/biomedicines9080992

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop